Taysha Gene Therapies, Inc. (TSHA)
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.8M
- Net income
- -$109.0M
- Total assets
- $343.3M
- Market cap
- $1.6B
- Operating margin
- -1130.6%
- Net margin
- -1115.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.8M
- Operating expenses
- $120.3M
- Operating income
- -$110.5M
- Income tax
- $0
- Net income
- -$109.0M
- EPS (basic)
- $-0.34
- EPS (diluted)
- $-0.34
Balance sheet
- Total assets
- $343.3M
- Current assets
- $324.6M
- Total liabilities
- $96.4M
- Current liabilities
- $26.6M
- Shareholders’ equity
- $246.9M
Cash flow
- Operating cash flow
- -$93.1M
- Investing cash flow
- -$604.0K
- Financing cash flow
- $274.6M
- Net cash flow
- $180.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-0.34
- Shares outstanding
- 286.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 24, 2020
Taysha Gene Therapies, Inc. (TSHA) Stock Price
- Reported a net loss of $109.0M in FY2025.
- Trading 21% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Taysha Gene Therapies, Inc..
Write a review
News about Taysha Gene Therapies, Inc.
News & sentiment via Polygon.io
Taysha Gene Therapies, Inc.: frequently asked questions
Is Taysha Gene Therapies, Inc. an American company?
Taysha Gene Therapies, Inc. is a US-based company headquartered in Dallas, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc. is headquartered in Dallas, Texas, United States.
Is Taysha Gene Therapies, Inc. publicly traded?
Yes — Taysha Gene Therapies, Inc. is a publicly traded company. Its stock trades under the ticker symbol TSHA on the NASDAQ.
What does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
